TCRT ALAUNOS THERAPEUTICS INC Management Changes 8-K Filing 2024 - Appointment of Interim CEO Alaunos Therapeutics, Inc. appointed Dale Curtis Hogue, Jr. as Interim Chief Executive Officer, effective January 20, 2024, with an annual base salary of $250,000 and an option to purchase 600,000 shares of common stock.Get access to all SEC 8-K filings of the ALAUNOS THERAPEUTICS INC